Capital Rx, a New York-based health technology company, raised $106M in Series C funding.
B Capital was the lead investor, with participation from General Catalyst Transformation Capital and Edison Partners. In conjunction with the funding, Dr. Robert Mittendorff, General Partner and Head of Healthcare at B Capital, joined the company’s Board of Directors. B Capital Principal Nick Whitehead and Holly Maloney, Managing Director at General Catalyst, will join as board observers.
The funds will be used by the company to expand and accelerate its growth.
Capital Rx is headed by AJ Loiacono (CEO), who aims to transform the way prescription drugs and patients are treated. Its enterprise pharmacy platform JUDI™ connects every aspect of the pharmacy ecosystem in one system, plan build, implementation, claims adjudication, data exchange, prior authorization, client reporting, billing/reimbursement, member tools and more, enabling patient engagement and increasing efficiency to achieve the highest standards of clinical care.